Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
- 15 June 2019
- journal article
- review article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 14 (4) , 346-351
Abstract
Alleviating cytopenias, namely anemia, is the main goal of therapy in lower-risk myelodysplastic syndromes (MDS). Current available treatment options remain limited. We review the role of TGF-B pathway in MDS, the current available data on luspatercept and sotatercept development.Keywords
This publication has 31 references indexed in Scilit:
- Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal womenThe Journal of Clinical Pharmacology, 2013
- miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signalingBlood, 2013
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsBlood, 2011
- Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I KinaseCancer Research, 2011
- A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeysBone, 2010
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2009
- Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDSBlood, 2008
- Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive TherapyJournal of Clinical Oncology, 2008
- TGFβ–SMAD signal transduction: molecular specificity and functional flexibilityNature Reviews Molecular Cell Biology, 2007
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006